Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.87 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3569406 | 0.93 | LMNA (1.00) | SIRT6LMNAPOLBMAPTALDH1A1 | |
| SCHEMBL7155984 | 0.92 | POLB (0.84) | SIRT6LMNAPOLBMAPTALDH1A1 | |
| SCHEMBL4638282 | 0.92 | SIRT6 (0.84) | SIRT6LMNAPOLBMAPTALDH1A1 | |
| SCHEMBL15271381 | 0.90 | SIRT6 (0.81) | SIRT6LMNAPOLBMAPTALDH1A1 | |
| SCHEMBL6151230 | 0.90 | SIRT6 (0.81) | SIRT6LMNAPOLBMAPTALDH1A1 | |
| SCHEMBL11171262 | 0.89 | SIRT6 (0.81) | SIRT6LMNAPOLBMAPTALDH1A1 | |
| SCHEMBL5466738 | 0.89 | SIRT6 (0.79) | SIRT6LMNAPOLBMAPTALDH1A1 | |
| SCHEMBL12240580 | 0.85 | SIRT6 (0.74) | SIRT6LMNAPOLBMAPTALDH1A1 | |
| SCHEMBL13247587 | 0.85 | SIRT6 (0.73) | SIRT6LMNAPOLBMAPTALDH1A1 | |
| SCHEMBL7048817 | 0.85 | MAPT (0.85) | SIRT6LMNAPOLBMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118371269-A | Piperazine ligand modified gold-based catalyst and application thereof in hydrochlorination of acetylene | 鄂尔多斯市瀚博科技有限公司 | 2024-07-23 | — | — | CN | claimed |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| US-20250339425-A1 | Alpha9 and Alpha7 Nicotinic Acetylcholine Receptor Ligands | UNIV NORTHEASTERN (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4612148-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| US-20250257070-A1 | NOVEL SULFONAMIDE DERIVATIVE WITH FUSED PYRIMIDINE SKELETON, HAVING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION INHIBITORY EFFECT | HANMI PHARM. CO., LTD. (KR) | 2025-08-14 | — | — | US | disclosed |
| US-20250214987-A1 | THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2025-07-03 | — | — | US | disclosed |
| US-12319695-B2 | Sulfonamide derivative with fused pyrimidine skeleton, having epidermal growth factor receptor mutation inhibitory effect | HANMI PHARM. CO., LTD. (KR) | 2025-06-03 | — | — | US | disclosed |
| CN-119707835-A | 2-Aminopyrimidine-5-carboxamide compounds and use thereof for the production of medicaments for the treatment and/or prophylaxis of cancer | 沈阳药科大学 | 2025-03-28 | — | — | CN | disclosed |
| EP-4501915-A1 | THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR | Korea University Research and Business Foundation (KR) | 2025-02-05 | — | — | EP | disclosed |
| CN-118974021-A | Preparation method of thiobenzimidazole derivative and novel intermediate for same | 高丽大学校产学协力团 | 2024-11-15 | — | — | CN | disclosed |
| EP-1056732-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| EP-0995741-A1 | REMEDIES/PREVENTIVES FOR FREQUENT URINATION/URINARY INCONTINENCE AND TROPONE DERIVATIVES | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999021845-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
| US-5240780-A | Pressure sensitive adhesives | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-08-31 | — | — | US | disclosed |
| US-4906634-A | Novel N-[4-(aminosubstituted)phenyl]methanesulfonamides and their use as cardiovascular agents | SCHERING A.G. (DE) | 1990-03-06 | — | — | US | disclosed |
| EP-0332570-A2 | Novel-N-(4-(Aminosubstituted)phenyl) methanesulfonamides and their use as cardiovascular agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-09-13 | — | — | EP | disclosed |
| EP-0327763-A2 | Colored salts of polymeric sulfonate polyanions and dye cations, and light-absorbing coatings made therewith | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-08-16 | — | — | EP | disclosed |
| US-4851526-A | ANTIARRYTHMIA, HYPOTENSIVE, ANTIISCHEMIC | SCHERING A.G. (DE) | 1989-07-25 | — | — | US | disclosed |
| EP-0306440-A2 | 1-(4-substituted phenyl)-1H-imidazoles as cardiovascular agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-03-08 | — | — | EP | disclosed |
| US-3947434-A | 9-(P-phenylazoanilino)-7-methyl-1H-imidazo[4,5-f]quinolines | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339425-A1 | Alpha9 and Alpha7 Nicotinic Acetylcholine Receptor Ligands | CHRNA9, CHRNA7, CHRNA1 | SIRT6 1079/4885LMNA 2807/4885POLB 3370/4885 |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | SIRT6 4605/4885LMNA 1830/4885POLB 458/4885 |
| US-20250214987-A1 | THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR | WEE1, WEE2, HADHB | SIRT6 2289/4885LMNA 4720/4885POLB 2184/4885 |
| US-12319695-B2 | Sulfonamide derivative with fused pyrimidine skeleton, having epidermal growth factor receptor mutation inhibitory effect | EGFR, FGFR1, FGFR3 | SIRT6 3433/4885LMNA 4573/4885POLB 1309/4885 |
| US-20250257070-A1 | NOVEL SULFONAMIDE DERIVATIVE WITH FUSED PYRIMIDINE SKELETON, HAVING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION INHIBITORY EFFECT | EGFR, FGFR1, FGFR3 | SIRT6 3400/4885LMNA 4590/4885POLB 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.